190 related articles for article (PubMed ID: 28087741)
21. Sensitizing hormone-refractory prostate cancer cells to drug treatment by targeting 14-3-3sigma.
Han B; Xie H; Chen Q; Zhang JT
Mol Cancer Ther; 2006 Apr; 5(4):903-12. PubMed ID: 16648560
[TBL] [Abstract][Full Text] [Related]
22.
Winter M; Rokavec M; Hermeking H
Cancer Res; 2021 Jul; 81(13):3621-3634. PubMed ID: 34224368
[TBL] [Abstract][Full Text] [Related]
23. CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2.
Pulukuri SM; Rao JS
Oncogene; 2006 Aug; 25(33):4559-72. PubMed ID: 16786000
[TBL] [Abstract][Full Text] [Related]
24. The cell cycle regulator 14-3-3σ opposes and reverses cancer metabolic reprogramming.
Phan L; Chou PC; Velazquez-Torres G; Samudio I; Parreno K; Huang Y; Tseng C; Vu T; Gully C; Su CH; Wang E; Chen J; Choi HH; Fuentes-Mattei E; Shin JH; Shiang C; Grabiner B; Blonska M; Skerl S; Shao Y; Cody D; Delacerda J; Kingsley C; Webb D; Carlock C; Zhou Z; Hsieh YC; Lee J; Elliott A; Ramirez M; Bankson J; Hazle J; Wang Y; Li L; Weng S; Rizk N; Wen YY; Lin X; Wang H; Wang H; Zhang A; Xia X; Wu Y; Habra M; Yang W; Pusztai L; Yeung SC; Lee MH
Nat Commun; 2015 Jul; 6():7530. PubMed ID: 26179207
[TBL] [Abstract][Full Text] [Related]
25. 14-3-3sigma is a p53-regulated inhibitor of G2/M progression.
Hermeking H; Lengauer C; Polyak K; He TC; Zhang L; Thiagalingam S; Kinzler KW; Vogelstein B
Mol Cell; 1997 Dec; 1(1):3-11. PubMed ID: 9659898
[TBL] [Abstract][Full Text] [Related]
26. 14-3-3 Sigma Protein Contributes to Hepatocyte Growth Factor-mediated Cell Proliferation and Invasion
Jung JY; Koh SA; Lee KH; Kim JR
Anticancer Res; 2022 Jan; 42(1):519-530. PubMed ID: 34969762
[TBL] [Abstract][Full Text] [Related]
27. 14-3-3σ attenuates RhoGDI2-induced cisplatin resistance through activation of Erk and p38 in gastric cancer cells.
Kim IK; Park SM; Cho HJ; Baek KE; Nam IK; Park SH; Ryu KJ; Ryu J; Choi J; Hong SC; Kim JW; Lee CW; Kang SS; Yoo J
Oncotarget; 2013 Nov; 4(11):2045-56. PubMed ID: 24185104
[TBL] [Abstract][Full Text] [Related]
28. Parp1-XRCC1 and the repair of DNA double strand breaks in mouse round spermatids.
Ahmed EA; de Boer P; Philippens ME; Kal HB; de Rooij DG
Mutat Res; 2010 Jan; 683(1-2):84-90. PubMed ID: 19887075
[TBL] [Abstract][Full Text] [Related]
29. ZNF281 is recruited on DNA breaks to facilitate DNA repair by non-homologous end joining.
Nicolai S; Mahen R; Raschellà G; Marini A; Pieraccioli M; Malewicz M; Venkitaraman AR; Melino G
Oncogene; 2020 Jan; 39(4):754-766. PubMed ID: 31570788
[TBL] [Abstract][Full Text] [Related]
30. c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias.
Muvarak N; Kelley S; Robert C; Baer MR; Perrotti D; Gambacorti-Passerini C; Civin C; Scheibner K; Rassool FV
Mol Cancer Res; 2015 Apr; 13(4):699-712. PubMed ID: 25828893
[TBL] [Abstract][Full Text] [Related]
31. Diallyl disulfide selectively causes checkpoint kinase-1 mediated G2/M arrest in human MGC803 gastric cancer cell line.
Ling H; Lu LF; He J; Xiao GH; Jiang H; Su Q
Oncol Rep; 2014 Nov; 32(5):2274-82. PubMed ID: 25176258
[TBL] [Abstract][Full Text] [Related]
32. XRN2 interactome reveals its synthetic lethal relationship with PARP1 inhibition.
Patidar PL; Viera T; Morales JC; Singh N; Motea EA; Khandelwal M; Fattah FJ
Sci Rep; 2020 Aug; 10(1):14253. PubMed ID: 32859985
[TBL] [Abstract][Full Text] [Related]
33. DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin.
Ciszewski WM; Tavecchio M; Dastych J; Curtin NJ
Breast Cancer Res Treat; 2014 Jan; 143(1):47-55. PubMed ID: 24292814
[TBL] [Abstract][Full Text] [Related]
34. BCL2-overexpressing prostate cancer cells rely on PARP1-dependent end-joining and are sensitive to combined PARP inhibitor and radiation therapy.
Oing C; Tennstedt P; Simon R; Volquardsen J; Borgmann K; Bokemeyer C; Petersen C; Dikomey E; Rothkamm K; Mansour WY
Cancer Lett; 2018 Jun; 423():60-70. PubMed ID: 29526801
[TBL] [Abstract][Full Text] [Related]
35. PARP1 Links CHD2-Mediated Chromatin Expansion and H3.3 Deposition to DNA Repair by Non-homologous End-Joining.
Luijsterburg MS; de Krijger I; Wiegant WW; Shah RG; Smeenk G; de Groot AJL; Pines A; Vertegaal ACO; Jacobs JJL; Shah GM; van Attikum H
Mol Cell; 2016 Feb; 61(4):547-562. PubMed ID: 26895424
[TBL] [Abstract][Full Text] [Related]
36. PCNA and JNK1-Stat3 pathways respectively promotes and inhibits diabetes-associated centrosome amplification by targeting at the ROCK1/14-3-3σ complex in human colon cancer HCT116 cells.
Lu YC; Wang P; Wang J; Ma R; Lee SC
J Cell Physiol; 2019 Jul; 234(7):11511-11523. PubMed ID: 30478982
[TBL] [Abstract][Full Text] [Related]
37. Negative cell cycle regulator 14-3-3sigma stabilizes p27 Kip1 by inhibiting the activity of PKB/Akt.
Yang H; Zhang Y; Zhao R; Wen YY; Fournier K; Wu HB; Yang HY; Diaz J; Laronga C; Lee MH
Oncogene; 2006 Aug; 25(33):4585-94. PubMed ID: 16532026
[TBL] [Abstract][Full Text] [Related]
38. TRIM25 is associated with cisplatin resistance in non-small-cell lung carcinoma A549 cell line via downregulation of 14-3-3σ.
Qin X; Qiu F; Zou Z
Biochem Biophys Res Commun; 2017 Nov; 493(1):568-572. PubMed ID: 28867193
[TBL] [Abstract][Full Text] [Related]
39. The absence of Ku but not defects in classical non-homologous end-joining is required to trigger PARP1-dependent end-joining.
Mansour WY; Borgmann K; Petersen C; Dikomey E; Dahm-Daphi J
DNA Repair (Amst); 2013 Dec; 12(12):1134-42. PubMed ID: 24210699
[TBL] [Abstract][Full Text] [Related]
40. Alternative NHEJ Pathway Components Are Therapeutic Targets in High-Risk Neuroblastoma.
Newman EA; Lu F; Bashllari D; Wang L; Opipari AW; Castle VP
Mol Cancer Res; 2015 Mar; 13(3):470-82. PubMed ID: 25563294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
